CA
NZ
UK
AU
IND
US
argenx SE (NASDAQ:ARGX), a global immunology company headquartered in Amsterdam, saw its shares climb toward 52 week highs following a wave of bullish analyst commentary. The advance follows the company's positive Phase 3 ALKIVIA topline results in autoimmune myositis, announced August 17.
BioArctic AB (OTC: BRCTF) (publ) is a leading biotechnology company with a market capitalization of approximately $29.3 billion. This change underscores BioArctic’s strong execution and potential within the healthcare sector. Investors are likely to find reassurance in the solid earnings performance, which contributes positively …
This approval applies to two new treatment regimens, specifically Ziihera combined with Tevimbra (tislelizumab-jsgr) and fluoropyrimidine-plus-platinum chemotherapy, which are recommended for HER2-positive patients with either IHC 3+ or IHC 2+/ISH+ status. This significant milestone introduces a new therapeutic option for a patient population in …
Vyome Holdings, Inc. (NASDAQ: HIND) recorded approximately $7.9 million in cash and cash equivalents as of June 30, 2026, marking a significant rise from approximately $5.0 million at the end of 2025. This improvement inLiquiditysupports the company’s operational strategy as it focuses on advancing …
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) has established September 4, 2026, as the record date for the distribution of contingent value rights (CVRs). This announcement comes as a significant step in connection with the company's intended merger with Korsana Biosciences, marking progress in the overall …
PDS Biotechnology Corp (NASDAQ: PDSB) is executing a significant workforce reduction that will affect about 36% of its employees, a strategic move made official on August 6, 2026. This reduction aligns the company’s operational costs with its shifting priorities, particularly focusing on the advancement …
Adaptin Bio, Inc. (OTC: APTN) has commenced enrollment for a Phase 1 clinical trial assessing its investigational therapy, APTN-101, for glioblastoma, an aggressive form of brain cancer. This study represents a critical step toward evaluating APTN-101’s safety and efficacy in treating this severe illness, …
Electromed, Inc. (AMEX: ELMD) achieved a record net revenue of $19.4 million during Q4 FY 2026, reflecting an impressive 11.6% increase compared to the $17.4 million reported in the same quarter last fiscal year. This achievement highlights the company's sustained growth trajectory and operational …
Spyre Therapeutics, Inc. (NASDAQ: SYRE) announced on August 25, 2026, that its Phase 2 SKYWAY basket trial's rheumatoid arthritis (RA) sub-study delivered promising topline results for SPY072. Both the Low and High Dose of SPY072 demonstrated statistically significant improvements over placebo in various key …
Bicara Therapeutics Inc. (NASDAQ: BCAX) has finalized a sublease agreement for roughly 35,090 square feet of office space, designed to serve as its new headquarters in Boston. This strategic move takes place at 10 St. James Avenue, positioning the firm for enhanced operational capabilities. …
Please wait processing your request...